National trends in keloid treatment revealed the greatest utilization of treatment among women and those in the finance and service industries.
No new safety concerns and consistent safety profiles were observed for long-term risankizumab use in patients with psoriasis and PsA.
The overall second primary malignancy point estimate was 5.8% for patients receiving chimeric antigen receptor T-cell therapy.